// App-Quantinova.ai

AB0632 (2018) : Essdai domain evaluation of primary sjÖgren’s syndrome (PSS patients enrolled in two independent poc studies indicates differential utility of domains for trial inclusion and composite endpoints in pss trials

Researchers

Presenter

  • T. Dörner

Principal Investigators

  • B.A. Fisher

  • X. Ren

  • P. Faerber

  • P. Gergely

  • L. Mooney

  • Y. Li

  • S.J. Oliver

  • W. Hueber

  • A.M. Wright

Medical Centers

  • Charite Hospital, Berlin, Germany

  • Rheumathology Research Group, University of Birmingham, Birmingham, United Kingdom

  • Novartis Institutes for BioMedical Research, MA

  • Novartis Pharma Corp, Basel, Switzerland

Locations

  • Germany

  • United Kingdom

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Sjogren's syndrome

Biomarkers

  • N/A

Drug/Treatment

  • Hydroxychloroquine

  • Oraprine

  • Methotrexate

  • Prednisone

  • CFZ-533

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • Novartis

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved